465 results on '"Ramkissoon, Shakti H."'
Search Results
2. Cancer Trials Ecosystem in India—Ready for Prime Time?
3. Clinical Laboratory Testing Practices in Diffuse Gliomas Prior to Publication of 2021 World Health Organization Classification of Central Nervous System Tumors
4. FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas
5. Erratum to: FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas
6. RNA Sequencing Identifies Novel NRG1 Fusions in Solid Tumors that Lack Co-Occurring Oncogenic Drivers
7. Validation of the Labcorp Plasma Focus Test to Facilitate Precision Oncology Through Cell-Free DNA Genomic Profiling of Solid Tumors
8. Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic alterations, TMB, and PD-L1.
9. Molecular analysis of endometrial serous carcinoma reveals distinct clinicopathologic and genomic subgroups
10. Evaluating tumor inflammation and PD-L1 expression in sequential biopsies of real-world primary and metastatic breast cancer.
11. Interaction between VEGF-A and immune checkpoint targets in triple-negative breast cancer and mechanisms of immune evasion and tumor progression.
12. Multi-specimen comprehensive genomic profiling for diagnostic disambiguation in advanced and metastatic solid tumors.
13. Novel HLA-Ilo/HLA-IIhi phenotype and immune evasion in triple-negative breast cancer.
14. A machine learning algorithm based on multi-omics biomarkers for the detection of tumor microsatellite instability.
15. Pervasive loss of antigen presentation in solid tumors driven by loss of HLA class I expression.
16. Clinicopathological and genomic characterization of BCORL1-driven high-grade endometrial stromal sarcomas
17. Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitors
18. Clinicopathologic and genomic characterization of PD-L1-positive uterine cervical carcinoma
19. Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary
20. Correlating ROS1 Protein Expression With ROS1 Fusions, Amplifications, and Mutations
21. CYLD mutation characterizes a subset of HPV-positive head and neck squamous cell carcinomas with distinctive genomics and frequent cylindroma-like histologic features
22. A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases
23. Real-world comprehensive genomic and immune profiling reveals distinct age- and sex-based genomic and immune landscapes in tumors of patients with non-small cell lung cancer.
24. HPV51-associated Leiomyosarcoma: A Novel Class of TP53/RB1-Wildtype Tumor With Predilection for the Female Lower Reproductive Tract
25. CYLD-mutant cylindroma-like basaloid carcinoma of the anus: a genetically and morphologically distinct class of HPV-related anal carcinoma
26. Genomic profiling of BCOR-rearranged uterine sarcomas reveals novel gene fusion partners, frequent CDK4 amplification and CDKN2A loss
27. Frequent inactivating mutations of the PBAF complex gene PBRM1 in meningioma with papillary features
28. Mechanisms and therapeutic implications of hypermutation in gliomas
29. Novel synthetic lethality drug target in urothelial bladder cancer based on MTAP genomic loss
30. Pan-cancer analysis of the effect of biopsy site on tumor mutational burden observations
31. SMARCA4 inactivation defines a subset of undifferentiated uterine sarcomas with rhabdoid and small cell features and germline mutation association
32. Comprehensive genetic alteration profiling in primary and recurrent glioblastoma
33. General paucity of genomic alteration and low tumor mutation burden in refractory and metastatic hepatoblastoma: comprehensive genomic profiling study
34. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic
35. Attenuating hypoxia driven malignant behavior in glioblastoma with a novel hypoxia-inducible factor 2 alpha inhibitor
36. Molecular and clinicopathologic features of gliomas harboring NTRK fusions
37. Data from Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model
38. Supplementary Figures 1 through 7 and Supplementary Table 1 from Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model
39. Supplementary Methods from Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model
40. Supplementary Figure Legends from Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model
41. Genomic characterization of recurrent high-grade astroblastoma
42. Adult Atypical Teratoid/Rhabdoid Tumors
43. Integrated Genomic Characterization of a Pineal Parenchymal Tumor of Intermediate Differentiation
44. POU2AF3 ‐rearranged Sarcomas: A Novel Tumor Defined by Fusions of EWSR1 or FUS to a Gene Formerly Designated COLCA2
45. Novel synthetic lethality drug target in urothelial bladder cancer based on MTAP genomic loss
46. Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery
47. Precision Neuro-oncology: the Role of Genomic Testing in the Management of Adult and Pediatric Gliomas
48. Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases
49. Disseminated glioneuronal tumors occurring in childhood: treatment outcomes and BRAF alterations including V600E mutation
50. Delivery of Functional Anti-miR-9 by Mesenchymal Stem Cell–derived Exosomes to Glioblastoma Multiforme Cells Conferred Chemosensitivity
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.